Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Immunotherapy
FcR gamma expression not required for HeFi-1-mediated tumor growth inhibition
October 5th, 2006
FcR gamma expression on polymorphonuclear leukocytes and monocytes is not required for HeFi-1-mediated tumor growth inhibition. According to a study from the United States, "CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy." "Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. "We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody,...
Source: Blood Weekly (2006-10-05)
|
